Trial Profile
A phase I study of radiotherapy concurrent with erlotinib (Tarceva) in the treatment of brain metastases from non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions
- 28 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2007 New trial record.